There are a large number of liver cancer patients in my country, and liver cancer is more likely to relapse after surgical resection, especially if it is accompanied by high-risk recurrence factors, such as multiple liver cancers, microvascular invasion (MVI) or macrovascular invasion, incomplete capsule, and the presence of satellite lesions , etc. This is especially true for patients. Therefore, in the treatment of liver cancer, doctors from the Oncology Department of Guangzhou Xinshi Hospital (The Third Affiliated Hospital of Guangdong Pharmaceutical University) advocate non-surgical treatment and tend to choose minimally invasive comprehensive treatment, combining minimally invasive tumor technology with Systemic treatments are combined to complement each other in the treatment of liver cancer.
Under normal circumstances, patients have different treatments according to different stages of the tumor. In many cases, surgical resection is recommended for early-stage tumors. In the treatment of liver cancer, due to the high recurrence rate after surgery, many patients are unwilling to undergo surgical resection. Similarly, for the treatment of liver cancer patients, doctors from the Oncology Department of the Third Hospital of Guangzhou Pharmaceutical also recommend that patients can undergo minimally invasive comprehensive treatment.
According to statistics, the survival period of patients can be improved through the cooperation of minimally invasive treatment and systemic treatment. Especially for patients with intermediate and advanced liver cancer, TACE technology combined with targeted therapy or immunotherapy is of great help in the treatment of patients with intermediate and advanced liver cancer. Professor Peng pointed out that the complexity and diversity of liver cancer determines that its treatment cannot be fixed. Doctors need to develop "personalized treatment" plans for different patients and different conditions.
TACE technology can accurately locate tumor cells, achieve local drug delivery, accurate drug delivery, block tumor nutrient supply, and provide targeted treatment for cancer cells while greatly reducing the toxic and side effects caused to patients during treatment. When doctors from the Oncology Department of the Third Hospital of Guangzhou Pharmaceutical combine targeted therapy, immunotherapy, and traditional Chinese medicine for patients, they choose appropriate treatment techniques based on the patient's condition and constitution, which can help improve the patient's immunity and strengthen the patient's system. Reduce the pain caused by cancer to patients, and at the same time enhance the effect of minimally invasive treatment to achieve a 1+12 effect.
